Bruton’s Tyrosine Kinase in B-Cell Malignancies: Advances in Targeted Therapy

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, introduce available BTK inhibitors used as targeted therapy in B-cell malignancies.

Drs Shadman and Cohen provide an overview of clinical trials utilizing the BTK inhibitor, ibrutinib, for B-cell lymphomas.

Two experts compare experiences and data concerning use of ibrutinib, acalabrutinib, and zanubrutinib in B-cell lymphomas.

Drs Shadman and Cohen discuss clinical trial data utilizing acalabrutinib in B-cell lymphomas.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, talk about disease progression on BTKi and what mechanisms of resistance can occur.

Drs Shadman and Cohen review clinical trials of zanubrutinib in B-cell lymphomas.

Two experts discuss use of ibrutinib and zanubrutinib and data from the ALPINE and ELEVATE-RR trials.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, share their preferences regarding BTK-targeted treatment in B-cell malignancies.

Drs Shadman and Cohen introduce new data concerning a third-generation BTK inhibitor, pirtobrutinib, and discuss unmet needs in the B-cell malignancy landscape.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, discuss possible future developments with BTKi as therapy options in B-cell lymphomas.